Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/6/2026

1. HUBS
2. WDC
3. SNDK
4. KVYO
5. APP
6. DASH
7. ZG
8. XYZ
9. DOX
10. PAYC

Go back to Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
(NASDAQ: QNRX) Delayed: 4.58 +0.21 (4.81%)
Previous Close $4.37    52 Week High $ 
Open $4.40    52 Week Low $ 
Day High $4.70    P/E N/A 
Day Low $4.33    EPS $ 
Volume 25,949